Drugs / Human Insulin NPH
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01790438 Comparator | Mar 2013 → May 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT00147836 Comparator | Sep 2004 → Oct 2007 | type 2 diabetes mellitus | Sun Yat-sen University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Insulin NPH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01790438 ↗ |
| Known as | Novolin-N | “Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime.” NCT00147836 ↗ |
| Modality | Protein / enzyme biologic | “Human insulin NPH will be used alone or in combination with up to 3 pre-study OAM(s) whose use is not excluded in combination with insulin.” NCT01790438 ↗ |
| Route | Subcutaneous | “Administered by SC injection once daily at bedtime.” NCT01790438 ↗ |